ATTO (Attovia Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ATTO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | COLIN WALSH | Director | MIXED | — | — |
| 2026-08-28 | GOLDMAN SACHS GROUP INC | — | MIXED | — | — |
| 2026-08-13 | COLIN WALSH | Director | MIXED | — | — |
| 2026-08-13 | West Street Life Sciences I, L.P. | — | MIXED | — | — |
| 2026-08-10 | DAVID KROIN | 10%+ Owner | C | — | — |
| 2026-08-10 | venBio Global Strategic Fund IV, L.P. | 10%+ Owner | MIXED | — | — |
| 2026-08-07 | Sanofi | 10%+ Owner | MIXED | — | — |
| 2026-08-07 | Redmile Group, LLC | 10%+ Owner | MIXED | — | — |
| 2026-08-07 | Sanofi | 10%+ Owner | MIXED | — | — |
| 2026-08-07 | Jeremy Green | 10%+ Owner | MIXED | — | — |
| 2026-08-06 | Hubert Chen | Chief Medical Officer | A | — | — |
| 2026-08-06 | Attovia Therapeutics, Inc. | President and CEO | A | — | — |
| 2026-08-06 | MITCHELL GOLD | Director | A | — | — |
| 2026-08-06 | Petter Veiby | Chief Scientific Officer | A | — | — |
| 2026-08-06 | Attovia Therapeutics, Inc. | Chief Financial Officer | A | — | — |
| 2026-08-06 | Zaneta Odrowaz | Chief Business Officer | A | — | — |
| 2026-08-06 | FHMLS XI, L.L.C. | 10%+ Owner | MIXED | — | — |
| 2026-08-06 | Angie You | Director | A | — | — |
| 2026-08-06 | Attovia Therapeutics, Inc. | Chief Financial Officer | A | — | — |
| 2026-08-06 | MITCHELL GOLD | Director | A | — | — |
| 2026-08-06 | Zaneta Odrowaz | Chief Business Officer | A | — | — |
| 2026-08-06 | Hubert Chen | Chief Medical Officer | A | — | — |
| 2026-08-06 | Attovia Therapeutics, Inc. | President and CEO | A | — | — |
| 2026-08-06 | Petter Veiby | Chief Scientific Officer | A | — | — |
| 2026-08-06 | Angie You | Director | A | — | — |
| 2026-08-06 | Frazier Life Sciences XI, L.P. | 10%+ Owner | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,565,978 | — |
| — | 10%+ Owner | 3,133,868 | — |
| — | 10%+ Owner | 2,165,708 | — |
| — | 10%+ Owner | 2,165,708 | — |
| — | 10%+ Owner | 1,957,138 | — |
| — | 10%+ Owner | 1,824,541 | — |
| — | 10%+ Owner | 1,082,855 | — |
| — | Director | 83,565 | — |
| — | — | 62,474 | — |
| — | — | 62,374 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATTO quote page; the site-wide leaderboard is on the insider transactions hub.